

## Vizimpro® (dacomitinib) - New orphan drug approval

- On September 27, 2018, <u>Pfizer announced</u> the <u>FDA approval</u> of <u>Vizimpro (dacomitinib)</u> for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
- Lung cancer is the leading cause of cancer death worldwide. NSCLC accounts for about 85% of lung cancer cases and remains difficult to treat, particularly in the metastatic setting. Approximately 75% of NSCLC patients are diagnosed late with metastatic or advanced disease where the five-year survival rate is only 5%.
- Dacomitinib is an irreversible inhibitor of the kinase activity of the human EGFR family (EGFR/HER1, HER2, and HER4) and certain EGFR activating mutations.
- The efficacy and safety of Vizimpro were demonstrated in an open-label clinical study of 452 patients with unresectable, metastatic NSCLC. Patients were randomized to Vizimpro or <a href="Iressa">Iressa</a>® (gefitinib) until disease progression or unacceptable toxicity. The primary efficacy outcome measure was progression-free survival (PFS). Other measures included overall response rate (ORR) and duration of response (DoR).
  - The Vizimpro group demonstrated a significantly greater PFS vs. the Iressa group (Hazard ratio = 0.59, 95% CI: 0.47, 0.74; p < 0.0001). The median PFS was 14.7 months (95% CI: 11.1, 16.6) with Vizimpro vs. 9.2 months (95% CI: 9.1, 11.0) with Iressa.</li>
  - The ORR was 75% (95% CI: 69, 80) with Vizimpro vs. 72% (95% CI: 65, 77) with Iressa (p = 0.39).
  - The median DoR was greater with Vizimpro vs. Iressa [14.8 months (95% CI: 12.0, 17.4) vs. 8.3 months (95 % CI: 7.4, 9.2), respectively].
  - An overall survival analysis was not conducted since the comparison of ORR was not statistically significant.
- Warnings and precautions of Vizimpro include interstitial lung disease, diarrhea, dermatologic adverse reactions, and embryo-fetal toxicity.
- The most common adverse reactions (> 20%) with Vizimpro use were diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, decreased weight, alopecia, cough, and pruritus.
- The recommended dosage of Vizimpro is 45 mg taken orally once daily, until disease progression or unacceptable toxicity occurs.
  - Refer to the Vizimpro drug label for dose reduction and modification recommendations for adverse reactions.
- Pfizer's launch date for Vizimpro is pending. Vizimpro will be available as 15 mg, 30 mg, and 45 mg tablets.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.